LABORATORIOS FARMACEUTICOS ROVI, S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 79.6 EUR | -1.06% |
|
-2.51% | +32.23% |
| Apr. 02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
| Mar. 12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
Evolution of the average Target Price on Laboratorios Farmaceuticos Rovi, S.A.
Price target over the last 5 years
History of analyst recommendation changes
0518ce89797b72.DYvoVg6jMIetrCfDcUhc42Jb5-3ZtNgC5aDlstOCUos.OcaACUqQfbGV6G32AQEOkRQOg5S2hqtaidbQ97q1B-pvwdscbMxTyOHiEw~4a5d65996432bd642d7619551f570287
Analysts' Consensus
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
79.6
EUR
Average target price
79.18
EUR
Spread / Average Target
-0.53%
High Price Target
100
EUR
Spread / Highest target
+25.63%
Low Price Target
66
EUR
Spread / Lowest Target
-17.09%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
B+
EPS Revisions
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ROVI Stock
- Consensus Laboratorios Farmaceuticos Rovi, S.A.
